Compare AGYS & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGYS | OGN |
|---|---|---|
| Founded | 1963 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.6B |
| IPO Year | 1994 | 2020 |
| Metric | AGYS | OGN |
|---|---|---|
| Price | $121.66 | $13.89 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | ★ $142.33 | $10.33 |
| AVG Volume (30 Days) | 288.3K | ★ 2.3M |
| Earning Date | 10-26-2026 | 10-30-2026 |
| Dividend Yield | N/A | ★ 0.58% |
| EPS Growth | ★ 67.07 | N/A |
| EPS | 0.78 | ★ 1.56 |
| Revenue | $319,312,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $17.70 | N/A |
| Revenue Next Year | $17.26 | $2.07 |
| P/E Ratio | $155.85 | ★ $8.91 |
| Revenue Growth | ★ 15.85 | N/A |
| 52 Week Low | $61.50 | $5.69 |
| 52 Week High | $129.32 | $13.90 |
| Indicator | AGYS | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 60.79 | 64.32 |
| Support Level | $103.53 | $13.72 |
| Resistance Level | $123.80 | N/A |
| Average True Range (ATR) | 4.81 | 0.05 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 73.98 | 90.63 |
Agilysys Inc is engaged in hospitality software, delivering cloud-native SaaS and on-premise solutions for hotels, multi-amenity resorts, cruise lines, casinos, corporate foodservice management, restaurants, universities, stadiums, and healthcare facilities. The Company's software solutions include point-of-sale (POS), property management (PMS), inventory and procurement, payments, and related applications that manage and enhance the entire guest journey. It operates across the Americas, Europe, the Middle East, Africa, Asia-Pacific, and India with headquarters located in Alpharetta, GA. The Company has one reportable segment serving the global hospitality industry.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.